Drug Approval | September 04, 2025
Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Subscribe To Our Newsletter & Stay Updated
